Guggenheim Cuts Billiontoone (NASDAQ:BLLN) Price Target to $100.00

Billiontoone (NASDAQ:BLLN) had its price target decreased by Guggenheim from $120.00 to $100.00 in a research note published on Monday morning,Benzinga reports. Guggenheim currently has a buy rating on the stock.

Several other research firms also recently weighed in on BLLN. JPMorgan Chase & Co. decreased their price objective on Billiontoone from $150.00 to $145.00 and set an “overweight” rating for the company in a report on Wednesday, December 10th. Weiss Ratings began coverage on shares of Billiontoone in a report on Tuesday, February 3rd. They issued a “sell (d)” rating on the stock. Stifel Nicolaus started coverage on shares of Billiontoone in a research report on Monday, December 1st. They issued a “buy” rating and a $145.00 price target for the company. Piper Sandler reiterated an “overweight” rating on shares of Billiontoone in a research note on Wednesday, December 10th. Finally, BTIG Research lowered their price objective on shares of Billiontoone from $160.00 to $140.00 and set a “buy” rating on the stock in a research report on Thursday, March 5th. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Billiontoone has a consensus rating of “Moderate Buy” and an average price target of $126.71.

Billiontoone Stock Performance

BLLN opened at $82.96 on Monday. Billiontoone has a one year low of $61.96 and a one year high of $138.70. The company has a debt-to-equity ratio of 0.12, a current ratio of 11.69 and a quick ratio of 11.32. The firm has a market capitalization of $3.81 billion and a PE ratio of 395.05. The business’s 50-day moving average price is $79.57.

Billiontoone (NASDAQ:BLLN) last announced its earnings results on Wednesday, March 4th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.07. The firm had revenue of $96.05 million during the quarter, compared to analyst estimates of $85.85 million. Billiontoone’s revenue was up 113.0% on a year-over-year basis.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd acquired a new position in shares of Billiontoone in the fourth quarter valued at approximately $230,000. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Billiontoone during the fourth quarter worth $8,277,000. Invesco Ltd. purchased a new position in Billiontoone in the 4th quarter valued at $15,535,000. XTX Topco Ltd purchased a new position in Billiontoone in the 4th quarter valued at $1,692,000. Finally, Quadrature Capital Ltd acquired a new position in Billiontoone in the 4th quarter valued at $614,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.